Which anabolic agents are indicated for osteoporosis in high‑risk patients, and what are their dosing schedules, contraindications, and required calcium and vitamin D supplementation?

Anabolic Agents for Osteoporosis in High-Risk Patients

For high-risk osteoporosis patients, initiate treatment with teriparatide (20 μg daily subcutaneous) or abaloparatide (80 μg daily subcutaneous) for up to 2 years, followed by mandatory anti-resorptive therapy (bisphosphonate or denosumab) to maintain bone gains, with concurrent calcium 1000-1500 mg/d and vitamin D 800-1200 IU/d supplementation. 1

Who Qualifies as High-Risk

High-risk patients requiring anabolic therapy include those with:

• Hip or vertebral fractures (clinical manifestation of severe disease)
• Very low T-scores (typically ≤-3.0)
• Fracture while on bisphosphonate therapy (treatment failure)
• Multiple clinical risk factors exceeding anabolic treatment thresholds
• Glucocorticoid-induced osteoporosis 2, 3

Available Anabolic Agents and Dosing

Currently Approved Agents

Teriparatide (PTH 1-34):

• Dose: 20 μg subcutaneous daily
• Duration: Up to 2 years maximum
• Efficacy: 66% reduction in vertebral fractures, 63% reduction in nonvertebral fractures 4

Abaloparatide (PTHrP analogue):

• Dose: 80 μg subcutaneous daily
• Duration: Up to 2 years maximum
• Similar efficacy profile to teriparatide with substantial BMD increases 1, 2

Romosozumab (Anti-sclerostin antibody):

• Most effective anabolic agent for rapid BMD gains
• Reduces spine fracture risk by 73% (OR: 0.27) at 12 months 5
• Currently approved in some jurisdictions, primarily for postmenopausal women 6

Important Nuance on Prior Bisphosphonate Use

The VERO trial subgroup analysis demonstrated that anabolic therapy remains effective even after prior bisphosphonate use, though the onset may be slightly delayed and magnitude somewhat blunted. Fracture reductions for vertebral and clinical fractures were similar in prior bisphosphonate users compared to treatment-naive patients 1. This is critical because many high-risk patients will have failed bisphosphonate therapy.

Contraindications and Precautions

Teriparatide and Abaloparatide:

• Avoid in patients with prior radiation therapy to skeleton
• Caution with hypercalcemia or hyperparathyroidism
• Most common side effects: headache and nausea (generally well tolerated) 2
• Historical concerns about osteosarcoma risk have been progressively downgraded 6

Romosozumab:

• Cardiovascular event concerns require careful patient selection 6
• Avoid in patients with recent myocardial infarction or stroke

Critical Sequencing Algorithm

The sequence of therapy is paramount:

1. Start with anabolic agent (teriparatide, abaloparatide, or romosozumab) for high-risk patients
2. Transition to anti-resorptive therapy after completing anabolic course (up to 2 years)
3. Never reverse this sequence - starting with anti-resorptives attenuates subsequent anabolic benefits 1, 2

Why this matters: Anabolic effects are rapidly lost after discontinuation (most effects wear off within 1 year of stopping), but anti-resorptive agents can maintain and possibly enhance the BMD gains achieved 1. Anti-resorptive follow-up options include bisphosphonates, denosumab, or raloxifene.

Required Calcium and Vitamin D Supplementation

All patients on anabolic therapy must receive:

• Elemental calcium: 1000-1500 mg daily
• Vitamin D: 800-1200 IU daily (some protocols use 400-1200 IU) 4, 7

This supplementation is non-negotiable - it serves as the foundational pillar for all osteoporosis management 8. Benefits are most apparent with the higher vitamin D dose (800 IU/day) complemented with 1000-1200 mg elemental calcium 7. These doses ensure adequate substrate for bone formation during anabolic therapy and prevent secondary hyperparathyroidism.

Common Pitfalls to Avoid

Daily injection adherence: Both teriparatide and abaloparatide require daily subcutaneous self-injection, which presents adherence challenges. Address this barrier upfront with patient education and support 1.

Cost barriers: Anabolic agents are substantially more expensive than other therapies, and insurance coverage may be limited. Document high-risk criteria clearly for prior authorization 1.

Forgetting anti-resorptive follow-up: The single most critical error is completing anabolic therapy without transitioning to anti-resorptive maintenance - this results in rapid bone loss and negates treatment benefits 1, 2.

Drug holidays: These are only possible in exceptional cases for high-risk patients and should generally be avoided 3.